Teriparatide as a chondroregenerative therapy for injury-induced osteoarthritis.

Sampson ER, Hilton MJ, Tian Y, Chen D, Schwarz EM, Mooney RA, Bukata SV, O'Keefe RJ, Awad H, Puzas JE, Rosier RN, Zuscik MJ

Science translational medicine1 Sept 2011Cited by 140 (Europe PMC)

PMID21937758PMCIDPMC3208271DOI10.1126/scitranslmed.3002214PepBankPUB-21937758

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with knee injury, teriparatide increased joint bone volume compared with saline-treated controls.
In plain wordsIn mice with knee injury, teriparatide increased joint bone volume compared with saline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseJoint bone volume
Study
mousen: not reported in source
Meniscal/ligamentous injury-induced knee osteoarthritis
Comparator
Saline-treated controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · systemicAs given in this study (mouse).
Source sentences
Summary
Microcomputed tomography revealed increased bone volume within joints from teriparatide-treated mice compared to saline-treated control animals.
2 context sentences(design, population, supporting numbers)
Summary · context
To test whether recombinant human PTH(1-34) (teriparatide) would inhibit aberrant chondrocyte maturation and associated articular cartilage degeneration, we administered systemic teriparatide (Forteo), a Food and Drug Administration-approved treatment for osteoporosis, either immediately after or 8…
Summary · context
Knee joints were harvested at 4, 8, or 12 weeks after injury to examine the effects of teriparatide on cartilage degeneration and articular chondrocyte maturation.
Report a problemFND-2193775801
02AnimalAnimal study (in vivo)Efficacy outcome
In mice with knee injury, immediate teriparatide administration increased proteoglycan content.
In plain wordsIn mice with knee injury, immediate teriparatide treatment increased cartilage proteoglycan content.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProteoglycan content after immediate treatment
Study
mousen: not reported in source
Meniscal/ligamentous injury-induced knee osteoarthritis
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · systemicAs given in this study (mouse).
Source sentences
Summary
Immediate systemic administration of teriparatide increased proteoglycan content and inhibited articular cartilage degeneration, whereas delayed treatment beginning 8 weeks after injury induced a regenerative effect.
2 context sentences(design, population, supporting numbers)
Summary · context
To test whether recombinant human PTH(1-34) (teriparatide) would inhibit aberrant chondrocyte maturation and associated articular cartilage degeneration, we administered systemic teriparatide (Forteo), a Food and Drug Administration-approved treatment for osteoporosis, either immediately after or 8…
Summary · context
Knee joints were harvested at 4, 8, or 12 weeks after injury to examine the effects of teriparatide on cartilage degeneration and articular chondrocyte maturation.
Report a problemFND-2193775802
03AnimalAnimal study (in vivo)Efficacy outcome
In mice with knee injury, immediate teriparatide administration inhibited articular cartilage degeneration.
In plain wordsIn mice with knee injury, immediate teriparatide treatment reduced cartilage degeneration.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseCartilage degeneration after immediate treatment
Study
mousen: not reported in source
Meniscal/ligamentous injury-induced knee osteoarthritis
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · systemicAs given in this study (mouse).
Source sentences
Summary
Immediate systemic administration of teriparatide increased proteoglycan content and inhibited articular cartilage degeneration, whereas delayed treatment beginning 8 weeks after injury induced a regenerative effect.
2 context sentences(design, population, supporting numbers)
Summary · context
To test whether recombinant human PTH(1-34) (teriparatide) would inhibit aberrant chondrocyte maturation and associated articular cartilage degeneration, we administered systemic teriparatide (Forteo), a Food and Drug Administration-approved treatment for osteoporosis, either immediately after or 8…
Summary · context
Knee joints were harvested at 4, 8, or 12 weeks after injury to examine the effects of teriparatide on cartilage degeneration and articular chondrocyte maturation.
Report a problemFND-2193775803
04AnimalAnimal study (in vivo)Efficacy outcome
In mice with knee injury, teriparatide treatment beginning 8 weeks after injury induced a regenerative effect.
In plain wordsIn mice with knee injury, delayed teriparatide treatment induced cartilage regeneration.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCartilage regeneration after delayed treatment
Study
mousen: not reported in source
Meniscal/ligamentous injury-induced knee osteoarthritis
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · systemicAs given in this study (mouse).
Source sentences
Summary
Immediate systemic administration of teriparatide increased proteoglycan content and inhibited articular cartilage degeneration, whereas delayed treatment beginning 8 weeks after injury induced a regenerative effect.
2 context sentences(design, population, supporting numbers)
Summary · context
To test whether recombinant human PTH(1-34) (teriparatide) would inhibit aberrant chondrocyte maturation and associated articular cartilage degeneration, we administered systemic teriparatide (Forteo), a Food and Drug Administration-approved treatment for osteoporosis, either immediately after or 8…
Summary · context
Knee joints were harvested at 4, 8, or 12 weeks after injury to examine the effects of teriparatide on cartilage degeneration and articular chondrocyte maturation.
Report a problemFND-2193775804

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In mice with knee injury, teriparatide's cartilage effects correlated with decreased type X collagen expression.
In plain wordsIn mice with knee injury, teriparatide's cartilage effects were linked to lower type X collagen expression.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseType X collagen expression
Study
mousen: not reported in source
Meniscal/ligamentous injury-induced knee osteoarthritis
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The chondroprotective and chondroregenerative effects of teriparatide correlated with decreased expression of type X collagen, RUNX2 (runt-related transcription factor 2), matrix metalloproteinase 13, and the carboxyl-terminal aggrecan cleavage product NITEGE.
2 context sentences(design, population, supporting numbers)
Summary · context
To test whether recombinant human PTH(1-34) (teriparatide) would inhibit aberrant chondrocyte maturation and associated articular cartilage degeneration, we administered systemic teriparatide (Forteo), a Food and Drug Administration-approved treatment for osteoporosis, either immediately after or 8…
Summary · context
Knee joints were harvested at 4, 8, or 12 weeks after injury to examine the effects of teriparatide on cartilage degeneration and articular chondrocyte maturation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2193775805
06AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In mice with knee injury, teriparatide's cartilage effects correlated with decreased RUNX2 expression.
In plain wordsIn mice with knee injury, teriparatide's cartilage effects were linked to lower RUNX2 expression.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRUNX2 expression
Study
mousen: not reported in source
Meniscal/ligamentous injury-induced knee osteoarthritis
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The chondroprotective and chondroregenerative effects of teriparatide correlated with decreased expression of type X collagen, RUNX2 (runt-related transcription factor 2), matrix metalloproteinase 13, and the carboxyl-terminal aggrecan cleavage product NITEGE.
2 context sentences(design, population, supporting numbers)
Summary · context
To test whether recombinant human PTH(1-34) (teriparatide) would inhibit aberrant chondrocyte maturation and associated articular cartilage degeneration, we administered systemic teriparatide (Forteo), a Food and Drug Administration-approved treatment for osteoporosis, either immediately after or 8…
Summary · context
Knee joints were harvested at 4, 8, or 12 weeks after injury to examine the effects of teriparatide on cartilage degeneration and articular chondrocyte maturation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2193775806
07AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In mice with knee injury, teriparatide's cartilage effects correlated with decreased matrix metalloproteinase 13 expression.
In plain wordsIn mice with knee injury, teriparatide's cartilage effects were linked to lower matrix metalloproteinase 13 expression.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseMatrix metalloproteinase 13 expression
Study
mousen: not reported in source
Meniscal/ligamentous injury-induced knee osteoarthritis
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The chondroprotective and chondroregenerative effects of teriparatide correlated with decreased expression of type X collagen, RUNX2 (runt-related transcription factor 2), matrix metalloproteinase 13, and the carboxyl-terminal aggrecan cleavage product NITEGE.
2 context sentences(design, population, supporting numbers)
Summary · context
To test whether recombinant human PTH(1-34) (teriparatide) would inhibit aberrant chondrocyte maturation and associated articular cartilage degeneration, we administered systemic teriparatide (Forteo), a Food and Drug Administration-approved treatment for osteoporosis, either immediately after or 8…
Summary · context
Knee joints were harvested at 4, 8, or 12 weeks after injury to examine the effects of teriparatide on cartilage degeneration and articular chondrocyte maturation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2193775807
08AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In mice with knee injury, teriparatide's cartilage effects correlated with decreased NITEGE aggrecan cleavage product expression.
In plain wordsIn mice with knee injury, teriparatide's cartilage effects were linked to lower expression of the aggrecan cleavage product NITEGE.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNITEGE expression
Study
mousen: not reported in source
Meniscal/ligamentous injury-induced knee osteoarthritis
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The chondroprotective and chondroregenerative effects of teriparatide correlated with decreased expression of type X collagen, RUNX2 (runt-related transcription factor 2), matrix metalloproteinase 13, and the carboxyl-terminal aggrecan cleavage product NITEGE.
2 context sentences(design, population, supporting numbers)
Summary · context
To test whether recombinant human PTH(1-34) (teriparatide) would inhibit aberrant chondrocyte maturation and associated articular cartilage degeneration, we administered systemic teriparatide (Forteo), a Food and Drug Administration-approved treatment for osteoporosis, either immediately after or 8…
Summary · context
Knee joints were harvested at 4, 8, or 12 weeks after injury to examine the effects of teriparatide on cartilage degeneration and articular chondrocyte maturation.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2193775808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

WithdrawnPhase not statedNCT03217513

Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis

Edward Foxn = 0est. 1 Jan 2020 to est. 31 Dec 2024

Osteoporosis · Knee Osteoarthritis

Trial page ClinicalTrials.govUpdated 24 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.